Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
Horizon Discovery Group PLC
of the United Kingdom
sales of £58.73 million [US$71.71 million]
of which 79%
Eczacibasi Ilac Sanayi ve T.A.S.
(692.09 million Turkish Liras [US$117.88 million]
of which 80%
was Health), and
Moberg Pharma AB (publ)
based in Sweden
(439.04 million Swedish Kronor [US$44.08 million]
of which 40%
was Kerasal Nail /Nalox).
During the year ended December of 2018, sales at
Valneva SE were 113.04 million Euro (US$123.94 million).
increase of 7.4%
versus 2017, when the company's sales were 105.29 million Euro.
This was the fifth consecutive year of sales increases at Valneva SE
(and since 2013, sales have increased a total of 271%).
Sales of Commercialized Vaccines saw an increase
11.6% in 2018, from
92.91 million Euro to 103.65 million Euro.
Not all segments of Valneva SE experienced an increase in sales in 2018:
sales of Vaccine Candidates fell 64.9% to 2.63 million Euro.
Valneva SE also experienced decreases in sales in
Technologies and Services (down 27.8% to 6.75 million Euro)